Mai H. Le

2.4k total citations
26 papers, 589 citations indexed

About

Mai H. Le is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Mai H. Le has authored 26 papers receiving a total of 589 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 9 papers in Hematology. Recurrent topics in Mai H. Le's work include Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (6 papers) and Ubiquitin and proteasome pathways (6 papers). Mai H. Le is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Protein Degradation and Inhibitors (6 papers) and Ubiquitin and proteasome pathways (6 papers). Mai H. Le collaborates with scholars based in United States, Canada and Germany. Mai H. Le's co-authors include Adil Daud, Robert H. Pierce, Chris Twitty, Brian L. West, Christine A. Riedy, Philip Weinstein, Peter Milgrom, Paul Severson, Afshin Dowlati and David A. Karlin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Mai H. Le

26 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mai H. Le United States 12 236 219 200 93 74 26 589
Geertje J. D. van Mierlo Netherlands 13 742 3.1× 293 1.3× 169 0.8× 19 0.2× 21 0.3× 14 883
Rossella Fasano Italy 13 146 0.6× 178 0.8× 185 0.9× 47 0.5× 5 0.1× 20 522
Andrea Quaiser Germany 11 195 0.8× 342 1.6× 150 0.8× 66 0.7× 47 0.6× 20 459
N Duinkerken Netherlands 10 287 1.2× 119 0.5× 113 0.6× 156 1.7× 16 0.2× 15 539
Mirjana Urosevic‐Maiwald Switzerland 12 264 1.1× 190 0.9× 139 0.7× 9 0.1× 13 0.2× 24 583
Lori Clarke United States 8 144 0.6× 159 0.7× 262 1.3× 10 0.1× 42 0.6× 9 456
Robert Saddawi‐Konefka United States 13 431 1.8× 299 1.4× 207 1.0× 23 0.2× 11 0.1× 32 774
A J Infante United States 12 312 1.3× 97 0.4× 176 0.9× 34 0.4× 12 0.2× 21 629
Jayamanna Wickramasinghe United States 11 148 0.6× 212 1.0× 391 2.0× 22 0.2× 8 0.1× 14 648

Countries citing papers authored by Mai H. Le

Since Specialization
Citations

This map shows the geographic impact of Mai H. Le's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mai H. Le with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mai H. Le more than expected).

Fields of papers citing papers by Mai H. Le

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mai H. Le. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mai H. Le. The network helps show where Mai H. Le may publish in the future.

Co-authorship network of co-authors of Mai H. Le

This figure shows the co-authorship network connecting the top 25 collaborators of Mai H. Le. A scholar is included among the top collaborators of Mai H. Le based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mai H. Le. Mai H. Le is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mao, Weifeng, Bing Yao, Yanfeng Zhou, et al.. (2025). Abstract 4229: GTA182: A potentially best-in-class, MTA-cooperative PRMT5 inhibitor for MTAP-deleted advanced solid tumors. Cancer Research. 85(8_Supplement_1). 4229–4229. 1 indexed citations
2.
Martínez-Gutiérrez, Juan Carlos, Youngran Kim, Sergio Salazar‐Marioni, et al.. (2023). Automated Large Vessel Occlusion Detection Software and Thrombectomy Treatment Times. JAMA Neurology. 80(11). 1182–1182. 34 indexed citations
3.
Smith, Catherine C., Aaron D. Viny, Evan Massi, et al.. (2021). Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Clinical Cancer Research. 27(14). 4003–4011. 11 indexed citations
4.
Algazi, Alain P., Katy K. Tsai, Lawrence R. Chen, et al.. (2019). Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses. Cancer Immunology Research. 8(2). 246–254. 68 indexed citations
5.
Bhatia, Shailender, Natalie Miller, Rima M. Kulikauskas, et al.. (2019). Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma. Clinical Cancer Research. 26(3). 598–607. 70 indexed citations
6.
Canton, David A., Shawna A. Shirley, Jocelyn H. Wright, et al.. (2017). Melanoma Treatment with Intratumoral Electroporation of Tavokinogene Telseplasmid (pIL-12, Tavokinogene Telseplasmid). Immunotherapy. 9(16). 1309–1321. 41 indexed citations
7.
Algazi, Alain P., Katy K. Tsai, Lawrence R. Chen, et al.. (2016). Abstract CT134: Intratumoral electroporation of plasmid IL-12 can prime response to anti-PD1/PD-L1 blockade in patients with Stage III/IV-M1a melanoma. Cancer Research. 76(14_Supplement). CT134–CT134. 6 indexed citations
8.
Wesolowski, Robert, Nikunj Sharma, Brian L. West, et al.. (2016). A phase Ib study of pexidartinib (PLX3397) and weekly paclitaxel in patients with advanced solid tumors including an ovarian cancer subset. Gynecologic Oncology. 141. 121–121. 4 indexed citations
9.
Bhatia, Shailender, Jayasri G. Iyer, Dafina Ibrani, et al.. (2015). 504 Intratumoral delivery of Interleukin-12 DNA via in vivo electroporation leads to regression of injected and non-injected tumors in Merkel cell carcinoma: Final Results of a phase 2 study. European Journal of Cancer. 51. S104–S104. 10 indexed citations
10.
Rugo, Hope S., Nikunj Sharma, Brian L. West, et al.. (2014). Phase Ib Study of Plx3397, a Csf1R Inhibitor, and Paclitaxel in Patients with Advanced Solid Tumors. Annals of Oncology. 25. iv148–iv148. 4 indexed citations
11.
Sharma, Neelesh, Robert Wesolowski, Brian L. West, et al.. (2014). A phase 1b study to assess the safety of PLX3397, a CSF-1 receptor inhibitor, and paclitaxel in patients with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). TPS3127–TPS3127. 11 indexed citations
12.
Smith, Catherine C., Kimberly C. Lin, Elisabeth A. Lasater, et al.. (2013). Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML). Blood. 122(21). 3938–3938. 6 indexed citations
13.
Stewart, A. Keith, Andrzej Jakubowiak, Sundar Jagannath, et al.. (2011). The effect of carfilzomib (CFZ) in patients (Pts) with bortezomib (BTZ)-naive relapsed or refractory multiple myeloma (MM): Updated results from the PX-171-004 study.. Journal of Clinical Oncology. 29(15_suppl). 8026–8026. 5 indexed citations
14.
Vij, Ravi, Jonathan L. Kaufman, Andrzej Jakubowiak, et al.. (2010). Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients. Blood. 116(21). 1938–1938. 8 indexed citations
15.
Vij, Ravi, Lühua Wang, Robert Z. Orlowski, et al.. (2009). Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.. Blood. 114(22). 430–430. 13 indexed citations
16.
Le, Mai H., Christine A. Riedy, Philip Weinstein, & Peter Milgrom. (2009). Barriers to utilization of dental services during pregnancy: a qualitative analysis.. PubMed. 76(1). 46–52. 47 indexed citations
17.
18.
19.
Le, Mai H.. (2007). Polonium 210, exposed. Journal of Medical Toxicology. 3(2). 82–84. 6 indexed citations
20.
Flannery, Michael T., et al.. (2001). Endocarditis Due to Salmonella. Southern Medical Journal. 94(4). 427–428. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Geertje J. D. van Mierlo Breakdown of academic impact, for papers by Rossella Fasano Breakdown of academic impact, for papers by Andrea Quaiser Breakdown of academic impact, for papers by N Duinkerken Breakdown of academic impact, for papers by Mirjana Urosevic‐Maiwald Breakdown of academic impact, for papers by Lori Clarke Breakdown of academic impact, for papers by Robert Saddawi‐Konefka Breakdown of academic impact, for papers by A J Infante Breakdown of academic impact, for papers by Jayamanna Wickramasinghe
Rankless by CCL
2026